These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34452055)

  • 21. Personalized predictions of adverse side effects of the COVID-19 vaccines.
    Jamshidi E; Asgary A; Kharrazi AY; Tavakoli N; Zali A; Mehrazi M; Jamshidi M; Farrokhi B; Maher A; von Garnier C; Rahi SJ; Mansouri N
    Heliyon; 2023 Jan; 9(1):e12753. PubMed ID: 36597482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.
    Song JY; Cheong HJ; Kim SR; Lee SE; Kim SH; Noh JY; Yoon YK; Choi WS; Park DW; Sohn JW; Kim WJ; Kim MJ
    J Korean Med Sci; 2021 Apr; 36(15):e110. PubMed ID: 33876589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia.
    Almohaya AM; Qari F; Zubaidi GA; Alnajim N; Moustafa K; Alshabi MM; Alsubaie FM; Almutairi I; Alwazna Q; Al-Tawfiq JA; Barry M
    Prev Med Rep; 2021 Dec; 24():101595. PubMed ID: 34976653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review.
    Kroumpouzos G; Paroikaki ME; Yumeen S; Bhargava S; Mylonakis E
    Microorganisms; 2022 Mar; 10(3):. PubMed ID: 35336199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data.
    Sa S; Lee CW; Shim SR; Yoo H; Choi J; Kim JH; Lee K; Hong M; Han HW
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers.
    Kadali RAK; Janagama R; Peruru S; Malayala SV
    Int J Infect Dis; 2021 May; 106():376-381. PubMed ID: 33866000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.
    Shehab M; Alrashed F; Abdullah I; Alfadhli A; Ali H; Abu-Farha M; Channanath AM; Abubaker JA; Al-Mulla F
    Front Med (Lausanne); 2022; 9():881027. PubMed ID: 35755075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study.
    García-Grimshaw M; Ceballos-Liceaga SE; Hernández-Vanegas LE; Núñez I; Hernández-Valdivia N; Carrillo-García DA; Michel-Chávez A; Galnares-Olalde JA; Carbajal-Sandoval G; Del Mar Saniger-Alba M; Carrillo-Mezo RA; Fragoso-Saavedra S; Espino-Ojeda A; Blaisdell-Vidal C; Mosqueda-Gómez JL; Sierra-Madero J; Pérez-Padilla R; Alomía-Zegarra JL; López-Gatell H; Díaz-Ortega JL; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Clin Immunol; 2021 Aug; 229():108786. PubMed ID: 34147649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergy to COVID-19 vaccines: A current update.
    Cabanillas B; Novak N
    Allergol Int; 2021 Jul; 70(3):313-318. PubMed ID: 33962863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination.
    King ER; Towner E
    Am J Case Rep; 2021 Jul; 22():e931478. PubMed ID: 34285180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombosis post-mRNA-based SARS-CoV-2 vaccination (BNT162b2) - Time to think beyond thrombosis with thrombocytopenia syndrome (TTS).
    Yousaf Z; Ata F; Mohammed Hammamy RA
    Thromb Update; 2022 May; 7():100104. PubMed ID: 38620755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers.
    Otani J; Ohta R; Sano C
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy.
    Cox RE; Parish M; Oxencis C; Mckenna E; Thapa B; Chakrabarti S
    World J Clin Oncol; 2022 Jul; 13(7):599-608. PubMed ID: 36157156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.
    Puro V; Castilletti C; Agrati C; Goletti D; Leone S; Agresta A; Cimini E; Tartaglia E; Casetti R; Colavita F; Meschi S; Matusali G; Lapa D; Najafi Fard S; Aiello A; Farrone C; Gallì P; Capobianchi MR; Ippolito G; On Behalf Of The Inmi Covid-Vaccine Study Group
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34201065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany.
    Hoffmann MA; Wieler HJ; Enders P; Buchholz HG; Plachter B
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in Japan.
    Nishida Y; Hosomi S; Kobayashi Y; Nakata R; Ominami M; Nadatani Y; Fukunaga S; Otani K; Tanaka F; Nagami Y; Taira K; Kamata N; Fujiwara Y
    Healthcare (Basel); 2021 Dec; 10(1):. PubMed ID: 35052170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Propensity-Score-Matched Evaluation of Adverse Events Affecting Recovery after COVID-19 Vaccination: On Adenovirus and mRNA Vaccines.
    Son CS; Jin SH; Kang WS
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.
    García-Montero C; Fraile-Martínez O; Bravo C; Torres-Carranza D; Sanchez-Trujillo L; Gómez-Lahoz AM; Guijarro LG; García-Honduvilla N; Asúnsolo A; Bujan J; Monserrat J; Serrano E; Álvarez-Mon M; De León-Luis JA; Álvarez-Mon MA; Ortega MA
    Vaccines (Basel); 2021 Apr; 9(5):. PubMed ID: 33925526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine.
    Chilimuri S; Mantri N; Shrestha E; Sun H; Gongati S; Zahid M; Kelly P
    Am J Case Rep; 2021 Jul; 22():e933003. PubMed ID: 34304240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.